Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dioscorea bulbifera polysaccharide (DBLP) is a bioactive carbohydrate extract derived from the tubers of *Dioscorea bulbifera* L., a plant traditionally utilized in Chinese medicine (commonly known as air potato). Composed primarily of glucose, galacturonic acid, and galactose, DBLP is being investigated as a therapeutic adjuvant in oncology, particularly for cervical cancer. Preclinical studies indicate that DBLP possesses intrinsic anti-tumor properties and acts synergistically with cyclophosphamide (CTX) to enhance tumor growth inhibition. Mechanistically, it functions as an immunomodulator by protecting the thymus and spleen from chemotherapy-induced atrophy and modulating T-cell subpopulation ratios. Additionally, DBLP serves as an antioxidant, significantly increasing superoxide dismutase (SOD) activity and reducing markers of oxidative stress and tissue damage, such as malondialdehyde (MDA) and lactate dehydrogenase (LDH).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dioscorea bulbifera polysaccharide.